This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agrawal, M. Articles by Chen, C. C. Search for Related Content PubMed PubMed Citation Articles by Agrawal, M. Articles by Chen, C. C.

Increased ^99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 [M. A., F. M. B., M. E., S. B., T. F.]; Mary Babb Cancer Center, West Virginia University, Charleston, West Virginia [J. A.]; Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel [W. D. S.]; and Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 [C. C. C.]

^99mTc-sestamibi, a substrate of the multidrug transporter P-glycoprotein (Pgp), has been used as a functional imaging agent for the multidrug resistance-1 (MDR1) phenotype. In vitro, retention of ^99mTc-sestamibi by cells that overexpress Pgp can be enhanced by the addition of Pgp inhibitors. XR9576 (Tariquidar) is a potent and selective noncompetitive inhibitor of Pgp that is active at 25–80 nM. A Phase I trial of XR9576 in combination with vinorelbine (Navelbine) was conducted in 26 patients with metastatic cancers. A ^99mTc-sestamibi scan was obtained at baseline followed 48–96 h later by a second scan 1–3 h after the administration of XR9576. Time activity curves and areas under the curves (AUCs) were obtained for tumor, liver, lung, and heart, and tissue:heart AUC ratios were calculated. XR9576 enhanced ^99mTc-sestamibi accumulation and retention in the liver of all but two patients with a mean change of +128%. Furthermore, in 13 of 17 patients with tumor masses visible by ^99mTc-sestamibi, the tumor:heart ^99mTc-sestamibi AUC_{0–3 h} increased after the administration of XR9576, with increases of 36–263% seen in 8 patients. We conclude that in vivo administration of XR9576 inhibits ^99mTc-sestamibi efflux in both the normal liver and in drug resistant tumors. This study provides convincing evidence of the existence of XR9576-inhibitable ^99mTc-sestamibi efflux in a large fraction of drug resistant tumors. One can predict that efflux of Pgp substrates also occurs in these tumors. XR9576 provides an efficient way to inhibit this efflux and offers the potential to increase drug exposure in human cancer.

This article has been cited by other articles:

				J. Abraham, M. Edgerly, R. Wilson, C. Chen, A. Rutt, S. Bakke, R. Robey, A. Dwyer, B. Goldspiel, F. Balis, et al. A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine Clin. Cancer Res., May 15, 2009; 15(10): 3574 - 3582. [Abstract] [Full Text] [PDF]

				D. M. Hermann Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 167 - 179. [Abstract] [PDF]

				J. P. Bankstahl, C. Kuntner, A. Abrahim, R. Karch, J. Stanek, T. Wanek, W. Wadsak, K. Kletter, M. Muller, W. Loscher, et al. Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with (R)-11C-Verapamil and PET J. Nucl. Med., August 1, 2008; 49(8): 1328 - 1335. [Abstract] [Full Text] [PDF]

				C. Bolzati, M. Cavazza-Ceccato, S. Agostini, S. Tokunaga, D. Casara, and G. Bandoli Subcellular Distribution and Metabolism Studies of the Potential Myocardial Imaging Agent [99mTc(N)(DBODC)(PNP5)]+ J. Nucl. Med., August 1, 2008; 49(8): 1336 - 1344. [Abstract] [Full Text] [PDF]

				S. Shukla, C.-P. Wu, K. Nandigama, and S. V. Ambudkar The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2 Mol. Cancer Ther., December 1, 2007; 6(12): 3279 - 3286. [Abstract] [Full Text] [PDF]

				E. F. Choo, D. Kurnik, M. Muszkat, T. Ohkubo, S. D. Shay, J. N. Higginbotham, H. Glaeser, R. B. Kim, A. J. J. Wood, and G. R. Wilkinson Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1012 - 1018. [Abstract] [Full Text] [PDF]

				L. Hong, Y. Piao, Y. Han, J. Wang, X. Zhang, Y. Du, S. Cao, T. Qiao, Z. Chen, and D. Fan Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 Mol. Cancer Ther., December 1, 2005; 4(12): 1936 - 1942. [Abstract] [Full Text] [PDF]

				V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]

				D. Peer, Y. Dekel, D. Melikhov, and R. Margalit Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models Cancer Res., October 15, 2004; 64(20): 7562 - 7569. [Abstract] [Full Text] [PDF]

				S. E. Bates, S. Bakke, M. Kang, R. W. Robey, S. Zhai, P. Thambi, C. C. Chen, S. Patil, T. Smith, S. M. Steinberg, et al. A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2004; 10(14): 4724 - 4733. [Abstract] [Full Text] [PDF]

				A. Pichler, J. L. Prior, and D. Piwnica-Worms Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine PNAS, February 10, 2004; 101(6): 1702 - 1707. [Abstract] [Full Text] [PDF]

				G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]